Results 251 to 260 of about 113,542 (365)

Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants

open access: yesClinical Pharmacology in Drug Development, Volume 15, Issue 2, February 2026.
Abstract Asciminib is the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP) in patients with chronic myeloid leukemia. This phase 1, two‐treatment‐period, drug‐drug interaction study evaluated the effect of steady‐state asciminib on the pharmacokinetics of atorvastatin.
Matthias Hoch   +9 more
wiley   +1 more source

Evaluation of clinical cardiac safety of zilurgisertib, an activin receptor‐like kinase‐2 (ALK2) inhibitor, in healthy participants

open access: yesClinical Pharmacology in Drug Development, Volume 15, Issue 2, February 2026.
Abstract The oral, small molecule inhibitor of activin receptor‐like kinase‐2, zilurgisertib (INCB000928), is under evaluation in fibrodysplasia ossificans progressiva. Cardiac safety was assessed using electrocardiogram (ECG) parameters and a plasma concentration‐heart rate‐corrected QT (C‐QTc) interval analysis of pooled data from single ascending ...
Yan‐ou Yang   +5 more
wiley   +1 more source

Large Language Models for Clinical Trial Protocol Assessments

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 393-402, February 2026.
The purpose was to evaluate the utility of large language models (LLMs) for reviewing the statistical analysis plan (SAP) and pharmacokinetics–pharmacodynamics (PK–PD) components of clinical trial protocols. Clinical trial protocols and SAPs were obtained from clinicaltrials.gov for a testbed of 15 small‐molecule drugs, biologics, and global antibiotic
Euibeom Shin   +2 more
wiley   +1 more source

Drug‐Induced QT Prolongation: Associations Between Risk Classifications in a Swedish Clinical Decision Support System and Clinical Outcomes

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 503-513, February 2026.
Potential adverse drug events can be signaled in Clinical Decision Support Systems (CDSSs). This study validated a Swedish CDSS (Janusmed Risk Profile) by investigating associations between calculated risk classifications of drugs with QT‐prolonging potential and registered related clinical outcomes.
Ola Nordqvist   +6 more
wiley   +1 more source

A retrospective study on laboratory‐confirmed acute Chinese medicine poisoning involving aconite in Hong Kong from 2008 to 2020

open access: yesHong Kong Journal of Emergency Medicine, Volume 33, Issue 1, February 2026.
Abstract Background Territory‐wide epidemiological studies of acute Chinese medicine poisoning involving aconite after 2010 are lacking. Objectives To characterise the latest trends, presumed causes, clinical presentations, healthcare utilisation and patient outcomes of such poisoning cases in Hong Kong.
Rex Pui Kin Lam   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy